Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours

European Journal of Endocrinology, Supplement

Volumn 156, Issue 1, 2007, Pages

  Colao, Annamaria ^a   Filippella, Mariagiovanna ^b   Pivonello, Rosario ^a   Di Somma, Carolina ^a   Faggiano, Antongiulio ^a   Lombardi, Gaetano ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Aosta Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; OCTREOTIDE; QUINAGOLIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5;

ACROMEGALY; ACTH SECRETING ADENOMA; ADD ON THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CUSHING DISEASE; DATA BASE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG MEGADOSE; GROWTH HORMONE SECRETING ADENOMA; HUMAN; HYPOPHYSIS TUMOR; META ANALYSIS; MONOTHERAPY; NONFUNCTIONING PITUITARY ADENOMA; SYSTEMATIC REVIEW; THYROTROPIN SECRETING ADENOMA; UNSPECIFIED SIDE EFFECT;

ADENOMA; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; HUMANS; PITUITARY NEOPLASMS; RECEPTORS, DOPAMINE; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 34249019847     PISSN: 08044635     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02348     Document Type: Conference Paper

References (59)

1. Missale C, Nash SR, Robinson SW, Jaber M & Caron MG. Dopamine receptors: from structure to function. Physiological Reviews 1998 78 189-225.
2. Guillemin R & Gerich JE. Somatostatin: physiological and clinical significance. Annual Review of Medicine 1976 27 379-388.
3. Greenman Y & Melmed S. Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR 5 expression in the mammosomatotroph linage. Journal of Clinical Endocrinology and Metabolism 1994 79 724-729.
4. Greenman Y & Melmed S. Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. Journal of Clinical Endocrinology and Metabolism 1994 78 398-403.
5. Bression D, Brandi AM, Martres MP, Nousbaum A, Cesselin F, Racadot J & Peillon F. Dopaminergic receptors in human prolactin-secreting adenomas: a quantitative study. Journal of Clinical Endocrinology and Metabolism 1980 51 1037-1044.
6. Bression D, Brandi AM, Nousbaum A, Le Dafniet M, Racadot J & Peillon F. Evidence of dopamine receptors in huam growth hormone (GH)-secreting adenomas with concomitant study of dopamine inhibition of GH secretion in a perfusion system. Journal of Clinical Endocrinology and Metabolism 1982 55 589-593.
7. Bevan JS & Burke CW. Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine. Clinical Endocrinology 1986 25 561-572.
8. Hofland LJ & Lamberts SW. Somatostatin receptor subtype expression in human tumors. Annals of Oncology 2001 12 (Suppl. 2) S31-S36.
9. De Herder WW & Lamberts SWJ. Somatostatin and somatostatin analogues: diagnostic and therapeutic uses. Current Opinion in Oncology 2002 14 53-57.
10. Lamberts SWJ. Somatostatin analogs: their role in the treatment of growth hormone hypersecretion and excessive body growth. Growth Regulation 1991 1 3-10.
11. Stefaneanu L, Kovacs K, Horvath E, Buchfelder M, Fahlbusch R & Lancranjan L. Dopamine D2 receptor gene expression in human adenohypophysial adenomas. Endocrine 2001 14 329-336.
12. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I & Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group New England Journal of Medicine 1994 331 904-909.
13. Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L & Lombardi G. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. Journal of Clinical Endocrinology and Metabolism 1997 82 876-883.
14. Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML, Arvigo M, Annunziato L, Lombardi G, Colao A, Hofland LJ & Lamberts SW. Dopamine receptor expression and function in corticotroph pituitary tumors. Journal of Clinical Endocrinology and Metabolism 2004 89 2452-2462.
15. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC & Patel YC. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000 288 154-157.
16. Colao A, Ferone D, Marzullo P, Di Sarno A, Cerbone G, Sarnacchiaro F, Cirillo S, Merola B & Lombardi G. Effect of different domaminergic agents in the treatment of acromegaly. Journal of Clinical Endocrinology and Metabolism 1997 82 518-523.
17. Flogstad AK, Halse J, Grass P, Abisch E, Djoseland O, Kutz K, Bodd E & Jervell J. A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly. Journal of Clinical Endocrinology and Metabolism 1994 79 461-465.
18. Renner U, Mojto J, Lange M, Muller OA, von Werder K & Stalla GK. Effect of bromocriptine and SMS 201-995 on growth of human somatotrophic and non-functioning pituitary adenoma cells in vitro. European Journal of Endocrinology 1994 130 80-91.
19. Wagenaar AH, Harris AG, van der Lely AJ & Lamberts SW. Dynamics of the acute effects of octreotide, bromocriptine and both drugs in combination on growth hormone secretion in acromegaly. Acta Endocrinologica 1991 125 637-642.
20. Sadoul JL, Thyss A & Freychet P. Invasive mixed growth hormone/prolactin secreting pituitary tumor: complete shrinking by octreotide and bromocriptine, and lack of tumor growth relapse 20 months after octreotide withdrawal. Acta Endocrinologica 1992 126 179-183.
21. Cremonini N, Graziano E, Chiarini V, Sforza A & Zampa GA. Atypical McCune-Albright syndrome associated with growth hormone-prolactin pituitary adenoma: natural history, long-term follow-up, and SMS 201-995-bromocriptine combined treatment results. Journal of Clinical Endocrinology and Metabolism 1992 75 1166-1169.
22. Lombardi G, Colao A, Ferone D, Sarnacchiaro F, Marzullo P, Di Sarno A, Rossi E & Merola B. CV 205-502 treatment in therapy-resistant acromegalic patients. European Journal of Endocrinology 1995 132 559-564.
23. Marzullo P, Ferone D, Di Somma C, Pivonello R, Filippella M, Lombardi G & Colao A. Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary 1999 1 115-120.
24. Cozzi R, Attanasio R, Lodrini S & Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clinical Endocrinology 2004 61 209-215.
25. Selvarajah D, Webster J, Ross R & Newell-Price J. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. European Journal of Endocrinology 2005 152 569-574.
26. Jaffe CA & Barkan AL. Treatment of acromegaly with dopamine agonists. Endocrinology and Metabolism Clinics of North America 1992 21 713-735.
27. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C & Beckers A. Cabergoline in treatment of acromegaly: a study in 54 patients. Journal of Clinical Endocrinology and Metabolism 1998 83 374-378.
28. Howlett TA, Robertson IJA, Liddicoat A. Acromegaly: shrinkage of macroadenomas with cabergoline (abstract). Proceedings of the Endocrine Society 79th Annual Meeting. Mineapolis June 1997.
29. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S & Rabinowtiz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. Journal of Clinical Endocrinology and Metabolism 2005 90 4465-4473.
30. Lamberts SW, Zweens M, Verschoor L & del Pozo E. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs. Journal of Clinical Endocrinology and Metabolism 1986 63 16-19.
31. Fredstorp L, Kutz K & Werner S. Treatment with octreotide and bromocriptine in patients with acromegaly: an open pharmacodynamic interaction study. Clinical Endocrinology 1994 41 103-108.
32. Ferone D, Pivonello R, Lastoria S, Faggiano A, Del Basso de Caro ML, Cappabianca P, Lombardi G & Coalo A. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy. Clinical Endocrinology 2001 54 469-477.
33. Zatelli MC, Piccin D, Tagliati F, Bottoni A, Ambrosio MR, Margutti A, Scanarini M, Bondanelli M, Culler MD & degli Uberti EC. Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro. Journal of Clinical Endocrinology and Metabolism 2005 35 333-341.
34. Klibanski A. Non-secreting pituitary tumors. Endocrinology and Metabolism Clinics of North America 1987 16 793-804.
35. Koga M, Nakao H, Arao M, Stato B, Noma K, Morimoto Y, Kishimoto S, Mori S & Uozumi T. Demostration of specific dopamine receptors on human pituitary adenomas. Acta Endocrinologica 1987 114 595-602.
36. Bevan JS, Webster J, Burke CW & Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocrine Reviews 1992 13 221-240.
37. Grossman A, Ross R, Charlesworth M, Adams CB, Wass JA, Doniach I & Besser GM. The effect of dopamine agonist therapy on large functionless pituitary tumours. Clinical Endocrinology 1985 22 679-686.
38. Ferone D, Lastoria S, Colao A, Varrella P, Cerbone G, Acampa W, Merola B, Salvatore M & Lombardi G. Correlation of scintigraphic results, using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 1998 83 248-252.
39. Hedner P & Valdemarsson S. Reduced size of a hormonally silent pituitary adenoma during treatment with CV 205-502, a new dopamine agonist mainly stimulating D2 receptors. Neurosurgery 1989 25 948-950.
40. Nobels FR, de Herder WW, van den Brink WM, Kwekkeboom DJ, Hofland LJ, Zuyderwijk J, de Jong FH & Lamberts SW. Long-term treatment with the dopamine agonist quinagolide of patients with clinically non-functioning pituitary adenoma. European Journal of Endocrinology 2000 143 615-621.
41. Lamberts SW, Uitterlinden P & Del Pozo E. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years. Journal of Clinical Endocrinology and Metabolism 1987 65 703-710.
42. Lamberts SW, Bakker WH, Reubi JC & Krenning EP. Somatostatin receptor imaging in localization of endocrine tumors. New England Journal of Medicine 1990 323 1246-1249.
43. Faglia G, Bazzoni N, Spada A, Arosio M, Ambrosi B, Spinelli F, Sara R, Bonino C & Lunghi F. In vivo detection of somatostatin receptors in patients with functionless pituitary adenomas by means of a radioiodinated analog of somatostatin ([131] SDZ 204-090). Journal of Clinical Endocrinology and Metabolism 1991 73 850-856.
44. Plockinger U, Reichel M, Fett U, Saeger W & Quabbe HJ. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: Effect on tumor volume and lack of correlation with immohistochemistry and somatostatin receptor scintigraphy. Journal of Clinical Endocrinology and Metabolism 1994 74 1416-1423.
45. Colao A, Lastoria S, Ferone D, Varrella P, Marzullo P, Pivonello P, Cerbone G, Acampa W, Salvatore M & Lombardi G. The pituitary uptake of 111-DTPA-D-Phel-octreotide in the normal pituitary and in pituitary adenomas. Journal of Endocrinological Investigation 1999 22 176-183.
46. Warnet A, Harris AG, Renard E, Martin D, James-Deidier A & Chaumet-Riffaud P. A prospective multicenter trial of octreotide in 24 patients with visual defects caused by nonfunctioning and gonadotropin-secreting pituitary adenomas. The French Multicenter Octreotide Study Group. Neurosurgery 1997 41 786-797.
47. Vance ML, Ridgeway EC & Thorner MO. Follicle-stimulating hormone and a-subunit-secreting pituitary tumor treated with bromocriptine. Journal of Clinical Endocrinology and Metabolism 1985 61 580-584.
48. Kwekkeboom DJ & Lamberts SW. Long-term treatment with the dopamine agonist CV 205-502 of patients with a clinically non-functioning, gonadotroph, or a-subunit secreting pituitary adenoma. Clinical Endocrinology 1992 36 171-176.
49. Ferone D, Lastoria S, Colao A, Varrella P, Cerbone G, Acampa W, Merola B, Salvatore M & Lombardi G. Correlation of scintigraphic results using 123I-metoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 1998 83 248-252.
50. Lohmann T, Trantakis C, Biesold M, Prothmann S, Guenzel S, Schober R & Paschke R. Minor tumor shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline. Pituitary 2001 4 173-178.
51. Pivonello R, Martone C, Filippella M, Cavallo LM, Di Somma C, Cappabianca P, Colao A, Annunziato L & Lombardi G. Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. Journal of Clinical Endocrinology and Metabolism 2004 89 1674-1683.
52. Liuzzi A, Dallabonzana D & Oppizzi G. GIs there a real medical treatment for the 'non-secreting' pituitari adenomas? (abstract) Journal of Endocrinological Investigation 1991 14 (suppl. 1) 18.
53. De Bruin TW, Kwekkeboom DJ, Van't Verlaat JW, Reubi JC, Krenning EP, Lamberts SW & Croughs RJ. Clinically non functioning pituitary adenoma and octreotide response to long-term high dose treatment, and studies in vitro. Journal of Clinical Endocrinology and Metabolism 1992 75 1310-1317.
54. Warnet A, Timsit J, Chanson P, Guillausseau PJ, Zamfirescu F, Harris AG, Derome P, Cophignon J & Lubetzki J. The effect of somatostatin analogue on chiasmal dysfunction from pituitary macroadenomas. Journal of Neurosurgery 1989 71 687-690.
55. Andersen M, Bjerre P, Schroder HD, Edal A, Hoilund-Carlsen PF, Pedersen PH & Hagen C. In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas. Clinical Endocrinology 2001 54 23-30.
56. Ducati A, Losa M, Fava E, Cenzato M & Giovannelli M. Acute effects on visual function of a somatostatin analog (SMS 201-995) evaluated using a neurophsiological approach (abstrct). Journal of Endocrinological Investigation 1991 14 (suppl. 1) 120.
57. Colao A, Ferone D, Lastoria S, Cerbone G, Di Sarno A, Di Somma C, Lucci R & Lombardi G. Hormone levels and tumor size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically nonfunctioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide. Clinical Endocrinology 2000 52 437-445.
58. van der Hoek J, de Herder WW, Feelders RA, van der Lely AJ, Uitterlinden P, Boerlin V, Bruns C, Poon KW, Lewis I, Weckbecker G, Krahnke T, Hofland LJ & Lamberts SW. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. Journal of Clinical Endocrinology and Metabolism 2004 89 638-645.
59. Arnaldi G, Polenta B, Cardinaletti M & Boscaro M. Potential indications for somatostatin analogs in Cushing's syndrome. Journal of Endocrinological Investigation 2005 28 (Suppl. 11) 106-110.